Lactulose

Generic Name: Lactulose

Brand Names: Constulose, Enulose, Generlac, Kristalose

Drug Type: Small Molecule

Chemical Formula: C_₁₂H_₂₂O_₁₁

CAS Number: 4618-18-2

Unique Ingredient Identifier: 9XH2P2N8EP

Background: Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE). Despite being first synthesized in 1929, investigations regarding its possible use as a laxative for the treatment of chronic constipa...

Indication: Lactulose is indicated for use as a laxative in the treatment of chronic constipation in adults and geriatric patients.
...

Associated Conditions: Constipation, Hepatic Encephalopathy (HE)

Associated Therapies: -

Clinical Trials

Study of Lactulose in Children With Chronic Liver Disease

Phase 2

Terminated

Conditions: Minimal Hepatic Encephalopathy

Interventions: Drug: placebo
Drug: Lactulose

First Posted Date: 2008-12-19

Last Posted Date: 2014-02-10

Lead Sponsor: Indiana University

Target Recruit Count: 16

Registration Number: NCT00811434

Locations: 🇺🇸
James Whitcomb Riley Hospital for Children, INdianapolis,, Indiana, United States

Rifaximin Versus Lactulose in Renal Failure

Phase 4

Withdrawn

Conditions: Renal Failure
Liver Cirrhosis

Interventions: Drug: Rifaximin
Drug: Lactulose

First Posted Date: 2008-09-09

Last Posted Date: 2022-02-08

Lead Sponsor: Weill Medical College of Cornell University

Registration Number: NCT00748904

Locations: 🇺🇸
Weill Cornell Medical Center, New York, New York, United States

Lactulose Supplementation in Premature Infants

Phase 2

Completed

Conditions: Necrotizing Enterocolitis
Sepsis

Interventions: Dietary Supplement: Dextrose
Drug: Lactulose

First Posted Date: 2008-02-15

Last Posted Date: 2008-02-15

Lead Sponsor: Bnai Zion Medical Center

Target Recruit Count: 28

Registration Number: NCT00616876

Locations: 🇮🇱
NICU, Department of Neonatology, Bnai Zion Medical Center, Haifa, Israel

Safety and Efficacy of AST-120 Compared to Lactulose in Patients With Hepatic Encephalopathy

Phase 2

Completed

Conditions: Hepatic Encephalopathy

Interventions: Drug: AST-120
Drug: lactulose

First Posted Date: 2007-11-14

Last Posted Date: 2014-05-30

Lead Sponsor: Ocera Therapeutics

Target Recruit Count: 40

Registration Number: NCT00558038

Locations: 🇺🇸
University of Massachusetts Medical School, Worchester, Massachusetts, United States
🇺🇸
McGuire VA Medical Center, Richmond, Virginia, United States
🇺🇸
Mount Sinai School of Medicine, New York, New York, United States

and more 13 locations

Lactulose for the Prevention of Hepatic Encephalopathy in Cirrhotic Patients With Upper Gastrointestinal Hemorrhage

Phase 3

Conditions: Hepatocerebral Encephalopathy
Portal-Systemic Encephalopathy
Encephalopathy, Hepatic
Encephalopathy, Hepatocerebral

Interventions: Drug: Placebo
Drug: Lactulose

First Posted Date: 2007-11-04

Last Posted Date: 2007-11-04

Lead Sponsor: Aga Khan University

Target Recruit Count: 128

Registration Number: NCT00553423

Locations: 🇵🇰
Aga Khan university, Karachi, Sind, Pakistan
🇵🇰
Aga Khan University, Karachi, Sind, Pakistan

A Clinical Standardization Study of the Preferred Acupuncture Treatment Protocol to Treat Functional Constipation

Phase 2

Completed

Conditions: Constipation

Interventions: Other: deep needling
Drug: Lactulose
Other: shallow needling

First Posted Date: 2007-07-30

Last Posted Date: 2014-06-04

Lead Sponsor: Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Target Recruit Count: 475

Registration Number: NCT00508482

Locations: 🇨🇳
Guang'an Men Hospital Affiliated to China Academy of Chinese Medical Sciences, Beijing, Beijing, China

Movicol in Childhood Constipation (ProMotion Study)

Phase 2

Completed

Conditions: Feces, Impacted

First Posted Date: 2006-11-27

Last Posted Date: 2007-01-04

Lead Sponsor: Norgine

Target Recruit Count: 60

Registration Number: NCT00403858

Locations: 🇬🇧
St Richard's Hospital, Royal West Sussex Hospital NHS Trust, Chichester, United Kingdom

Movicol in Childhood Constipation (ProMotion Study)

Phase 2

Completed

Conditions: Chronic Constipation

First Posted Date: 2006-11-27

Last Posted Date: 2006-11-28

Lead Sponsor: Norgine

Target Recruit Count: 60

Registration Number: NCT00404040

Locations: 🇬🇧
St Richard's Hospital, Royal West Sussex Hospital NHS Trust, Chichester, United Kingdom

Effect of Lactulose on Minimal Hepatic Encephalopathy and Health-Related Quality of Life

Phase 4

Completed

Conditions: Minimal Hepatic Encephalopathy
Hepatic Encephalopathy

First Posted Date: 2006-09-13

Last Posted Date: 2007-03-02

Lead Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh

Target Recruit Count: 80

Registration Number: NCT00375375

Locations: 🇮🇳
Postgraduate Institute of Medical Education and Research, Chandigarh, UT, India

RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial

Phase 3

Terminated

Conditions: Hepatic Encephalopathy

Interventions: Drug: Rifaximin
Drug: Lactulose
Other: Placebo

First Posted Date: 2006-08-16

Last Posted Date: 2019-09-17

Lead Sponsor: University of Miami

Target Recruit Count: 13

Registration Number: NCT00364689

Locations: 🇺🇸
Center For Liver Diseases - University of Miami, Miami, Florida, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy